^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Kidney Cancer

    Related cancers:
    1d
    CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Cdactin-O (CBM588)
    1d
    The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry (clinicaltrials.gov)
    P=N/A, N=600, Recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    1d
    E2810: Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery (clinicaltrials.gov)
    P3, N=129, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    pazopanib
    2d
    Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial (clinicaltrials.gov)
    P2, N=200, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
    Enrollment closed
    |
    Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    2d
    CALySSEY: CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors (clinicaltrials.gov)
    P1, N=88, Not yet recruiting, Baylor College of Medicine | Initiation date: Jan 2026 --> Jun 2026
    Trial initiation date
    2d
    Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov)
    P1/2, N=47, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    mTOR (Mechanistic target of rapamycin kinase)
    |
    Jingzhuda (entinostat) • Proleukin (aldesleukin)
    2d
    LIAM Mc: Linking In With Advice and Supports for Men Impacted by Metastatic Cancer (clinicaltrials.gov)
    P=N/A, N=72, Active, not recruiting, University College Cork | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2025 --> Mar 2026
    Enrollment closed • Trial primary completion date
    2d
    PRADR/ET22-313: Study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (2022-502440-12-00)
    P1/2, N=48, Completed, Centre Leon Berard, Centre Leon Berard | Active, not recruiting --> Completed
    Trial completion
    2d
    RUBIKID: Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma (clinicaltrials.gov)
    P2, N=50, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting
    Enrollment open
    |
    VEGFA (Vascular endothelial growth factor A) • CD34 (CD34 molecule)
    2d
    Flavokawain C suppresses nephroblastoma growth by inducing autophagy-mediated downregulation of FABP4 via AMPK/mTOR pathway. (PubMed, Sci Rep)
    The in vivo study further confirmed that FKC inhibited the growth of nephroblastoma. This study demonstrates that FKC inhibits the proliferation, migration, and invasion of nephroblastoma cells by inducing AMPK pathway-mediated autophagy, leading to the degradation of FABP4.
    Journal
    |
    FABP4 (Fatty Acid Binding Protein 4)
    3d
    Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder (clinicaltrials.gov)
    P2, N=87, Recruiting, Psyence Australia Pty Ltd | Trial completion date: Aug 2026 --> Jul 2027 | Trial primary completion date: May 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    3d
    CDFF332A12101: DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies (clinicaltrials.gov)
    P1, N=40, Terminated, Novartis Pharmaceuticals | Active, not recruiting --> Terminated; Business decision and not related to safety concerns
    Trial termination • IO biomarker • First-in-human
    |
    VHL (von Hippel-Lindau tumor suppressor) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • EPAS1 (Endothelial PAS domain protein 1) • SDHC (Succinate Dehydrogenase Complex Subunit C) • SDHD (Succinate Dehydrogenase Complex Subunit D) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A) • SDHAF2 (Succinate Dehydrogenase Complex Assembly Factor 2)
    |
    VHL mutation
    |
    everolimus • spartalizumab (PDR001) • DFF332 • taminadenant (NIR178)